RT Journal Article
SR Electronic
T1 Clinical echocardiography does not indicate cardiac dysfunction in critically ill Covid-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21261025
DO 10.1101/2021.07.23.21261025
A1 Isackson, Henrik
A1 Larsson, Anders
A1 Lipcsey, Miklos
A1 Frithiof, Robert
A1 Flachskampf, Frank A.
A1 Hultström, Michael
YR 2021
UL http://medrxiv.org/content/early/2021/07/26/2021.07.23.21261025.abstract
AB Aims We aimed to investigate the acute effects of severe SARS-CoV-2 on myocardial function.Methods and Results This is an observational study generated from the first 79 patients admitted to intensive care in Uppsala due to respiratory failure with SARS-CoV-2 infection, during the first wave in 2020, included in the PRONMED study. From this group 34 underwent echocardiographic examination of which 25 were included in the study, and compared to 44 non-echo patients. Demographic analysis compared standard parameters and previous morbidities between the echo and non-echo group. Standard echocardiographic parameters were analysed indicating a reduced left ventricular function as assessed by global longitudinal strain and very discrete increases in wall thickness in the group as a whole. A group comparison between the outcomes survival and death was carried out. Right sided dimensions and functional parameters did not indicate major strain. An increased maximum tricuspid valve regurgitation velocity indicating increased pulmonary arterial pressure was significantly associated with death, but failed to maintain significance when corrected for multiple comparison. Biochemical cardiac markers and D-dimer correlated to initiation of echocardiography and mortality. Tricuspid regurgitation maximum velocity was positively correlated with maximum troponin I.Conclusion These results suggests that there is no clear negative effect on cardiac function in critical SARS-CoV-2 infection. There are indications that pulmonary pressure elevation carries a negative predictive outcome suggesting pulmonary disease as the major driver of mortality. Cardiac biomarkers as well as D-dimer carry a predictive outcome value.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04316884Funding StatementThe study was funded by the SciLifeLab/KAW national Covid-19 research program project grants to MH (KAW 2020.0182 and KAW 2020.0241), and the Swedish Research Council to RF (2014-02569 and 2014-07606). HI was supported by the Swedish Society of Medical Research (SSMF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swedish National Ethical Review Agency EPM; 2020-01623All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the author upon reasonable requestAatrial transmitral diastolic velocityACE-2angiotensin converting enzyme 2ACEiangiotensin converting enzyme inhibitorARBangiotensin receptor blockerAngangiotensinBMIbody mass indexCovid-19corona virus disease 2019Eearly transmitral diastolic velocitye’medial tissue diastolic velocityEACVIEuropean association of cardiovascular imagingESCEuropean society of cardiologyFACfractional area changeGLSglobal longitudinal strainhs-TnIhigh sensitivity troponin IICUintensive care unitIVCinferior vena cavaIVC resp. variationinferior vena cava respiratory variationIVSDinterventricular septum diameterLAleft atriumLVleft ventricleLVEDDleft ventricular end diastolic diameterLVEFleft ventricular ejection fractionLVPWDleft ventricular posterior wall end diastolic diameterMV dec. timemitral valve deceleration timensnot significantNT-proBNPN-terminal pro brain natriuretic peptidePHpulmonary hypertensionPAATpulmonary artery acceleration timeRAright atriumRVright ventricleRVD1right ventricular basal diameterSARS-CoV-2severe acute respiratory syndrome corona virus 2TAPSEtricuspid annular peak systolic excursionTR Vmaxmaximum tricuspid regurgitation velocity